Patterns of anticoagulation use and cardioembolic risk after catheter ablation for atrial fibrillation

Journal of the American Heart Association

Volumn 4, Issue 11, 2015, Pages

  Noseworthy, Peter A ^a,b   Yao, Xiaoxi ^b   Deshmukh, Abhishek J ^a   Van Houten, Holly ^b   Sangaralingham, Lindsey R ^b   Siontis, Konstantinos C ^a   Piccini, Jonathan P ^d   Asirvatham, Samuel J ^a   Friedman, Paul A ^a   Packer, Douglas L ^a   Gersh, Bernard J ^a,d   Shah, Nilay D ^b,c  

^a Heart Rhythm Section   (United States)

^b Robert D and Patricia E Kern Center for Science of Health Care Delivery   (United States)

^c MAYO CLINIC   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Ablation; Anticoagulation; Atrial fibrillation; Stroke; Transient ischemic attack

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; RIVAROXABAN; WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; BRAIN HEMORRHAGE; CARDIOEMBOLISM; CARDIOVASCULAR DISEASE ASSESSMENT; CATHETER ABLATION; CEREBROVASCULAR ACCIDENT; CHA2DS2 VASC SCORE; CHARLSON COMORBIDITY INDEX; COMORBIDITY; CONTROLLED STUDY; DRUG WITHDRAWAL; EMBOLISM; FEMALE; HIGH RISK PATIENT; HUMAN; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PATIENT SAFETY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; ADOLESCENT; ADVERSE EFFECTS; CLINICAL PRACTICE; COMPLICATION; DRUG ADMINISTRATION; FACTUAL DATABASE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ORAL DRUG ADMINISTRATION; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; STROKE; TIME FACTOR; TREATMENT OUTCOME; TRENDS; UNITED STATES; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; CATHETER ABLATION; DATABASES, FACTUAL; DRUG ADMINISTRATION SCHEDULE; EMBOLISM; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PRACTICE PATTERNS, PHYSICIANS'; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; STROKE; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 85006218753     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.115.002597     Document Type: Article

References (32)

1. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64:e1-e76.
2. Al-Khatib SM, Allen LaPointe NM, Chatterjee R, Crowley MJ, Dupre ME, Kong DF, Lopes RD, Povsic TJ, Raju SS, Shah B, Kosinski AS, McBroom AJ, Sanders GD. Rate-and rhythm-control therapies in patients with atrial fibrillation: a systematic review. Ann Intern Med. 2014;160:760-773.
3. Verma A, Champagne J, Sapp J, Essebag V, Novak P, Skanes A, Morillo CA, Khaykin Y, Birnie D. Discerning the incidence of symptomatic and asymptomatic episodes of atrial fibrillation before and after catheter ablation (DISCERN AF): a prospective, multicenter study. JAMA Intern Med. 2013;173:149-156.
4. Pappone C, Vicedomini G, Augello G, Manguso F, Saviano M, Baldi M, Petretta A, Giannelli L, Calovic Z, Guluta V, Tavazzi L, Santinelli V. Radiofrequency catheter ablation and antiarrhythmic drug therapy: a prospective, randomized, 4-year follow-up trial: the APAF study. Circ Arrhythm Electrophysiol. 2011;4:808-814.
5. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Heldal M, Hohloser SH, Kolh P, Le Heuzey JY, Ponikowski P, Rutten FH. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31:2369-2429.
6. Wallace PJ, Shah ND, Dennen T, Bleicher PA, Crown WH. Optum Labs: building a novel node in the learning health care system. Health Aff. 2014;33:1187-1194.
7. Optum. Core US data assets. 2014. Available at: http://www.optum.com/content/dam/optum/resources/productSheets/5302_Data_Assets_Chart_Sheet_ISPOR.pdf. Accessed November 03, 2015.
8. Noseworthy PA, Kapa S, Deshmukh AJ, Madhavan M, Van Houten H, Haas LR, Mulpuru SK, McLeod CJ, Asirvatham SJ, Friedman PA, Shah ND, Packer DL. Risk of stroke after catheter ablation versus cardioversion for atrial fibrillation: a propensity-matched study of 24, 244 patients. Heart Rhythm. 2015;12:1154-1161.
9. Piccini JP, Sinner MF, Greiner MA, Hammill BG, Fontes JD, Daubert JP, Ellinor PT, Hernandez AF, Walkey AJ, Heckbert SR, Benjamin EJ, Curtis LH. Outcomes of Medicare beneficiaries undergoing catheter ablation for atrial fibrillation. Circulation. 2012;126:2200-2207.
10. Piccini JP, Hammill BG, Sinner MF, Jensen PN, Hernandez AF, Heckbert SR, Benjamin EJ, Curtis LH. Incidence and prevalence of atrial fibrillation and associated mortality among Medicare beneficiaries, 1993-2007. Circ Cardiovasc Qual Outcomes. 2012;5:85-93.
11. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137:263-272.
12. Tirschwell DL, Longstreth WT Jr. Validating administrative data in stroke research. Stroke. 2002;33:2465-2470.
13. Gialdini G, Nearing K, Bhave PD, Bonuccelli U, Iadecola C, Healey JS, Kamel H. Perioperative atrial fibrillation and the long-term risk of ischemic stroke. JAMA. 2014;312:616-622.
14. Fang MC, Go AS, Chang Y, Borowsky LH, Pomernacki NK, Udaltsova N, Singer DE. A new risk scheme to predict warfarin-associated hemorrhage: the ATRIA (anticoagulation and risk factors in atrial fibrillation) study. J Am Coll Cardiol. 2011;58:395-401.
15. 2-VASc score. J Am Coll Cardiol. 2015;65:1385-1394.
16. 2-VASc score (beyond sex) receive oral anticoagulation? J Am Coll Cardiol. 2015;65:635-642.
17. 2-VASc score of 1. J Am Coll Cardiol. 2015;65:225-232.
18. Themistoclakis S, Corrado A, Marchlinski FE, Jais P, Zado E, Rossillo A, Di Biase L, Schweikert RA, Saliba WI, Horton R, Mohanty P, Patel D, Burkhardt DJ, Wazni OM, Bonso A, Callans DJ, Haissaguerre M, Raviele A, Natale A. The risk of thromboembolism and need for oral anticoagulation after successful atrial fibrillation ablation. J Am Coll Cardiol. 2010;55:735-743.
19. Karasoy D, Gislason GH, Hansen J, Johannessen A, Kober L, Hvidtfeldt M, Ozcan C, Torp-Pedersen C, Hansen ML. Oral anticoagulation therapy after radiofrequency ablation of atrial fibrillation and the risk of thromboembolism and serious bleeding: long-term follow-up in nationwide cohort of Denmark. Eur Heart J. 2015;36:307-315.
20. Okumura Y. Which is the optimal therapy to prevent thromboembolism after atrial fibrillation ablation procedures in low stroke risk patients, anticoagulation or antiplatelet therapy? J Cardiovasc Electrophysiol. 2009;20:994-996.
21. Bunch TJ, Crandall BG, Weiss JP, May HT, Bair TL, Osborn JS, Anderson JL, Lappe DL, Muhlestein JB, Nelson J, Allison S, Foley T, Anderson L, Day JD. Warfarin is not needed in low-risk patients following atrial fibrillation ablation procedures. J Cardiovasc Electrophysiol. 2009;20:988-993.
22. Riley MP, Zado E, Hutchinson MD, Lin D, Bala R, Garcia FC, Callans DJ, Cooper JM, Verdino RJ, Dixit S, Marchlinski FE. Risk of stroke or transient ischemic attack after atrial fibrillation ablation with oral anticoagulant use guided by ECG monitoring and pulse assessment. J Cardiovasc Electrophysiol. 2014;25:591-596.
23. Saad EB, d'Avila A, Costa IP, Aryana A, Slater C, Costa RE, Inacio LA Jr, Maldonado P, Neto DM, Camiletti A, Camanho LE, Polanczyk CA. Very low risk of thromboembolic events in patients undergoing successful catheter ablation of atrial fibrillation with a CHADS2 score
24. Winkle RA, Mead RH, Engel G, Kong MH, Patrawala RA. Discontinuing anticoagulation following successful atrial fibrillation ablation in patients with prior strokes. J Interv Card Electrophysiol. 2013;38:147-153.
25. Cakulev I, Waldo AL. Do not stop the warfarin until. J Am Coll Cardiol. 2010;55:744-746.
26. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-891.
27. Calkins H, Brugada J, Packer DL, Cappato R, Chen SA, Crijns HJ, Damiano RJ Jr, Davies DW, Haines DE, Haissaguerre M, Iesaka Y, Jackman W, Jais P, Kottkamp H, Kuck KH, Lindsay BD, Marchlinski FE, McCarthy PM, Mont JL, Morady F, Nademanee K, Natale A, Pappone C, Prystowsky E, Raviele A, Ruskin JN, Shemin RJ. HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up. A report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Heart Rhythm. 2007;4:816-861.
28. January CT, Wann LS, Alpert JS, Calkins H, Cleveland JC Jr, Cigarroa JE, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;130:2071-2104.
29. Lakkireddy D, Reddy YM, Di Biase L, Vallakati A, Mansour MC, Santangeli P, Gangireddy S, Swarup V, Chalhoub F, Atkins D, Bommana S, Verma A, Sanchez JE, Burkhardt JD, Barrett CD, Baheiry S, Ruskin J, Reddy V, Natale A. Feasibility and safety of uninterrupted rivaroxaban for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. J Am Coll Cardiol. 2014;63: 982-988.
30. Di Biase L. Safety and efficacy of novel oral anticoagulants in the setting of atrial fibrillation ablation: is it time to celebrate the "funeral" of warfarin? J Interv Card Electrophysiol. 2014;41:103-105.
31. Hart RG, Pearce LA, Rothbart RM, McAnulty JH, Asinger RW, Halperin JL. Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. J Am Coll Cardiol. 2000;35:183-187.
32. Hohnloser SH, Pajitnev D, Pogue J, Healey JS, Pfeffer MA, Yusuf S, Connolly SJ. Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an active w substudy. J Am Coll Cardiol. 2007;50:2156-2161.